SCHEMBL2855458

SCHEMBL2855458

Nc1ccc(Oc2cc(NC(=O)C(F)(F)F)c(F)cc2Cl)nc1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.44
MEN1 O00255 3/20 0.44
POLB P06746 4/20 0.40
LMNA P02545 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
KDM4E B2RXH2 4/20 0.39
KEAP1 Q14145 1/20 0.38
ALOX5AP P20292 2/20 0.37
FEN1 P39748 2/20 0.37
GRM8 O00222 1/20 0.36
GRM7 Q14831 1/20 0.36
GRM4 Q14833 1/20 0.36
MAPT P10636 1/20 0.35
MAPK8 P45983 1/20 0.35
MAPK10 P53779 1/20 0.35
MET P08581 2/20 0.34
PTGS1 P23219 1/20 0.33
RAB9A P51151 1/20 0.33
PDE11A Q9HCR9 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2860402 0.88 MEN1 (0.47) KMT2AMEN1POLBLMNASMN1; SMN2
SCHEMBL2857702 0.83 HSPB1 (0.51) KMT2AMEN1POLBLMNASMN1; SMN2
SCHEMBL2453670 0.80 KDM4E (0.54) KMT2AMEN1POLBLMNAKDM4E
SCHEMBL2862343 0.80 BRAF (0.38) KMT2AMEN1POLBLMNASMN1; SMN2
SCHEMBL2855457 0.77 MEN1 (0.50) KMT2AMEN1POLBKDM4EKEAP1
SCHEMBL826431 0.77 SLC22A12 (0.39) KDM4E
SCHEMBL2857370 0.76 BRAF (0.48) PTGS1
SCHEMBL2861454 0.74 BRAF (0.45) SMN1; SMN2RAB9A
SCHEMBL3510993 0.72 KMT2A (0.43) KMT2AMEN1POLBLMNASMN1; SMN2
SCHEMBL1794731 0.71 MET (0.36) KMT2AMEN1POLBLMNAGRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2184285-B1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-11-04 EP disclosed
US-8344135-B2 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-01-01 US disclosed
US-20100249119-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-30 US disclosed
EP-2184285-A1 HETEROCYCLIC COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-05-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249119-A1 HETEROCYCLIC COMPOUND AND USE THEREOF BRAF, NRAS, RAF1 KMT2A 974/4885MEN1 627/4885POLB 4438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.